The impact of income inequality on the fertility intention: A micro perspective based on relative deprivation.

Autor: Li, Jun¹ (AUTHOR), Li, Tiantian¹ (AUTHOR) tiantianliltt@163.com, Wang, Wei¹ (AUTHOR)

Publikováno v: PLoS ONE. 12/5/2024, Vol. 19 Issue 12, p1-20. 20p.

The Amphibian Genomics Consortium: advancing genomic and genetic resources for amphibian research and conservation.

Autor: Kosch, Tiffany A.¹ (AUTHOR) tiffany.kosch@gmail.com, Torres-Sánchez, María² (AUTHOR) torressanchez.maria@gmail.com, Liedtke, H. Christoph³ (AUTHOR), Summers, Kyle⁴ (AUTHOR), Yun, Maximina H.^5,6 (AUTHOR), Crawford, Andrew J.^7,8 (AUTHOR), Maddock, Simon T.^9,10 (AUTHOR), Ahammed, Md. Sabbir¹¹ (AUTHOR), Araújo, Victor L. N.⁷ (AUTHOR), Bertola, Lorenzo V.¹² (AUTHOR), Bucciarelli, Gary M.¹³ (AUTHOR), Carné, Albert¹⁴ (AUTHOR), Carneiro, Céline M.¹⁵ (AUTHOR), Chan, Kin O.¹⁶ (AUTHOR), Chen, Ying¹⁷ (AUTHOR), Crottini, Angelica^18,19,20 (AUTHOR), da Silva, Jessica M.^21,22 (AUTHOR), Denton, Robert D.²³ (AUTHOR), Dittrich, Carolin²⁴ (AUTHOR), Espregueira Themudo, Gonçalo²⁵ (AUTHOR)

Publikováno v: BMC Genomics. 11/1/2024, Vol. 25 Issue 1, p1-19. 19p.

Granisetron as antiemetic therapy in children with cancer

Autor: J. Upward, O. B. Eden, Alan W. Craft, R. W. F. Campbell, D. M. Pierce, L. Price, Peter J. Shaw, R. Murdoch

Publikováno v: Medical and Pediatric Oncology. 25:28-32

The safety and efficacy of the new 5HT-3 antagonist granisetron as an antiemetic in children with cancer was evaluated in 40 children at a single dose of 40 μg/kg. No adverse affects attributable to the granisetron were noted. The overall major and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8842e50aeeab591d22d3f59e2e6eea79
https://doi.org/10.1002/mpo.2950250107

The pharmacokinetics of pranlukast in healthy young and elderly subjects

Autor: D R, Brocks, J, Upward, R, Hust, F E, Köester, H, Collie, Y, Qian, M J, Dennis

Publikováno v: International journal of clinical pharmacology and therapeutics. 34(9)

Pranlukast is a novel LTD4 antagonist under development for the treatment of asthma. To assess the effect of age, the pharmacokinetics of pranlukast were studied in healthy young (9 females, 10 males, mean 30 years) and elderly subjects (9 per sex, m

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::816d244b05ca39b98edf0e4ee8cec9e5
https://pubmed.ncbi.nlm.nih.gov/8880285

Pharmacokinetics and tolerability of ascending intravenous doses of granisetron, a novel 5-HT3 antagonist, in healthy human subjects

Autor: C. C. Asgill, A. Allen, B. D. Zussman, J. Upward, D. M. Pierce

Publikováno v: European Journal of Clinical Pharmacology. 46

The pharmacokinetics and tolerance of granisetron, a novel 5HT3-receptor antagonist which is under development as an anti-emetic agent have been studied after administration of single 30 min intravenous infusions to three groups of 8 healthy male sub

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7582d831ab0238fe282961bd8509ad4
https://doi.org/10.1007/bf00199881